Clinical Trials Logo

Influenza clinical trials

View clinical trials related to Influenza.

Filter by:

NCT ID: NCT02035696 Completed - Influenza Clinical Trials

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Start date: December 2013
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and immunogenicity of four influenza vaccines in children 6 months to < 48 months of age

NCT ID: NCT02026349 Completed - Influenza Clinical Trials

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

Start date: January 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.

NCT ID: NCT02019732 Completed - Influenza Clinical Trials

Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States

Start date: January 2013
Phase: N/A
Study type: Observational

This is a database study to quantify the burden of multiple mild outcomes (i.e., those that result in visits to a physician's office) attributable to influenza in the United States, stratified by age group, geographic region and influenza subtype for selected influenza seasons.

NCT ID: NCT02015494 Active, not recruiting - Influenza Clinical Trials

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

Start date: March 2014
Phase: Phase 1
Study type: Interventional

One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40 years of age.

NCT ID: NCT02014649 Terminated - Influenza Clinical Trials

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

FROSTY
Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2 protocol is designed to collect safety, tolerability and pharmacokinetic data of two doses of Laninamivir Octanoate in children and adolescents. The protocol will also explore virology and efficacy endpoints.

NCT ID: NCT02014168 Terminated - Influenza Clinical Trials

Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine

Start date: January 2014
Phase: Phase 1
Study type: Interventional

This is a single blinded placebo controlled phase I study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine MVA-NP+M1 with the Viroflu® seasonal influenza vaccine. All volunteers recruited will be healthy adults aged 18 and over.

NCT ID: NCT02008578 Completed - Influenza Clinical Trials

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

Start date: December 2013
Phase: Phase 1
Study type: Interventional

The purpose of this randomized, double-blind, placebo-controlled trial of intravenous hyperimmune immunoglobulin (Flu-IVIG) in individuals with influenza A or B is to determine the pharmacokinetic (PK) profile of Flu-IVIG and assess whether antibody levels observed following Flu-IVIG transfusion are similar to those predicted. This pilot study will inform a larger study that will be powered to compare Flu-IVIG with placebo for efficacy.

NCT ID: NCT02008344 Completed - Influenza Clinical Trials

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults

Start date: December 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.

NCT ID: NCT02000466 Withdrawn - Influenza Clinical Trials

FluLaval® Quadrivalent Pregnancy Registry

Start date: November 2013
Phase: N/A
Study type: Observational

The purpose of this pregnancy registry study is to detect and describe any abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with FluLaval Quadrivalent. The Registry requires voluntary, prospective reporting of eligible pregnancies by patients and health care providers (HCPs). Data such as vaccination with FluLaval Quadrivalent during pregnancy or within 28 days preceding conception, potential confounding factors (such as exposure to other medications) and information related to the outcome of the pregnancy will be collected prospectively.

NCT ID: NCT01999842 Completed - Influenza Clinical Trials

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Start date: November 25, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.